AUTHORS
Long Chang, MD, Yajing Lu2, Wei-tong Liu3, Yaguan Fan4, Fengjuan Li5, Dao-Bin Zhou6, Jiayi Liu7, Xinxin Cao, MD8
AFFILIATIONS
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
5 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
6 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
7 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
8 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
ABSTRACT
Background
Rosai-Dorfman disease (RDD) is a rare heterogeneous histiocytic disorder lacking standardized first-line treatment. Our prior single-center, prospective investigation (NCT 04924647) demonstrated the remarkable efficacy of combined lenalidomide and dexamethasone (RD) therapy in patients with RDD. The present study reports a multicenter prospective phase 2 clinical trial (NCT 07187167) together with an extended follow-up of earlier data conducted between June 2021 and December 2025.
Method
Sixty newly diagnosed and thirty-six recurrent RDD patients were enrolled. Lenalidomide 25mg days 1-21 plus dexamethasone 40mg days 1,8,15,22 was administered in 28-day cycles, totaling 12 cycles. Every patient received aspirin thromboprophylaxis during the RD treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR) to RD regimen, toxicity, and overall survival (OS) measured from RD start to death or last follow-up. The ?nal follow-up was June 1, 2026.
Result
The median age was 45 years (IQR 35-55), with 44.8% (n = 43) being male. Ninety-four patients (97.9%) exhibited extranodal RDD (10 unifocal, 21 single-system multifocal, 63 multi-system). A history of connective tissue disease was documented in 4 patients (4.2%). Median number of involved organs was 2 (range 1–7, IQR 1–3). The most frequently involved sites included lymph nodes (n = 39, 40.6%), subcutaneous tissue (n = 32, 33.3%), bone (n = 32, 33.3%), laryngopharynx (n = 25, 26.0%), sinus (n = 19, 19.8%) and central nervous system (CNS, n = 19, 19.8%). Among 84 patients undergoing next generation sequencing, MAP2K1, KRAS and BRAF non-V600E alterations were identified in 18 (21.4%) ,15 (14.3%) and 4 (4.8%) patients, respectively. Elevated C-reactive protein, IL-6, IL-10, TNF-α and IgG-4 were observed in 21.8% (19/87), 43.9% (36/82), 43.9% (36/82), 57.7% (45/78) and 12.7% (7/55) patients, respectively.
Patients received a median of 12 cycles therapy (IQR 6-12), while 12 (12.5%) went off protocol due to patient decision (n=6), disease progression (n=3) and adverse effect (n=3) before the last follow up. Among 85 evaluable patients, the ORR was 92.9%, comprising 43.5% complete remission and 49.4% partial remission as the best response. Five patients (5.2%) had stable disease (SD) and one (1.1%) had progressive disease (PD).
With a median follow up of 24 months (IQR 11-36), three patients in this cohort died (1 due to myocardial infarction, 1 due to COVID-19 and 1 due to CNS progression) and 12 experienced disease progression. The estimated 3- year OS and PFS rates were 96.1% and 76.8%, respectively. Univariate prognostic for PFS showed patients with 1-3 involved organs (3y PFS 81.8% vs 52.4%, HR 0.22, 95% CI 0.05–0.93, P=0.039) and those achieving CR (3y PFS 87.1% vs 58.7%, HR 0.12, 95% CI 0.03–0.33, P<0.001) exhibited better outcomes. Newly diagnosed patients tend to have better PFS than recurrent (3y PFS 84.4% vs 60.6%, HR 0.40, 95% CI 0.13–1.17, P<0.094).
Regarding adverse events, three patients discontinued RD therapy due to grade 3 adverse events (1 pulmonary embolism and 2 fatigue). Two patients experienced dose adjusted due to grade 3 myelosuppression. Twenty-six patients (27.0%) had grade 1-2 hematological toxicity. Other toxicities included rash (n=14, 14.5%), constipation (n=14, 14.5%), fatigue (n=12,12.5%), diarrhea (n=8,8.3%), glucose intolerance (n=8,8.3%) and edema (n=7, 7.3%).
Conclusion
Lenalidomide and dexamethasone combination regimen is a valid and safe regimen for RDD. Patients with 1-3 involved organs and achieving CR predict better outcomes.
DISCLOSURES
Long Chang, MD: No relevant conflicts of interest to declare.